Begelomab

Begelomab (SAND-26) is a murine IgG2b monoclonal antibody against DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy[1][2].

[1] Lorenzo RD, et, al. Begelomab for severe refractory dermatomyositis: A case report. Medicine (Baltimore). 2021 Mar 5;100(9):e24372. DOI:10.1097/MD.0000000000024372
[2] Ojha R, et, al. Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. Hum Immunol. 2022 Apr;83(4):346-355. DOI:10.1016/j.humimm.2022.01.004